chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Typical aches and weakness 48 hours after. Then was feeling like my head was in a fog for the next month or so. On December 5th, 5 days after the booster, after working out at work my heart rate and blood pressure would not go down. I went to the ER and doctor gave me cyproheptadine to lower my heart rate. It worked for my heart but my blood pressure remained high. Over the next weeks my blood pressure was staying on adversary around 150/100. I went to my primary doctor where they placed me and blood pressure medicine and to this day I?m still trying to adjust my blood pressure. The head fog seems to have dissipated but can come back on occasion.
ErythemaMultiform, UrticariaPruritus, 12/31-1/1 site redness and swelling, sore faded away. then returned on 1/6 red, swollen, itchy felt like big bug bite 1/7 hardened large circle swollen, erythema, itchy, dull pain. Narrative:  12/31-1/1 site redness swelling, sore faded away. then returned on 1/6 red, swollen, itchy felt like big bug bite 1/7 hardened large circle swollen, erythema, itchy, dull pain. Takes Flonase everyday, ice applied 1/6 with some relief.
Patient received a pediatric vaccine but was 12 at the time of vaccination. The 2nd dose was given correctly.
Hospitalized with Covid-19 on 09/14/2021 through 09/24/2021.
About 11 or 12 hours after receiving the vaccine, patient began a fever of 103.6 degrees and had severe chills.  He also developed nausea and a headache.  He then took his first Motrin(200 mg).  The following morning his fever temperature was 99.5 and by noon it was normal again.
Erythema, redness, swelling on left arm after 2-3 days.
Anti-GBM disease; This literature-non-study case was reported in a literature article and describes the occurrence of ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE (Anti-GBM disease) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.   LITERATURE REFERENCE:     No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to at an unspecified dose. On an unknown date, the patient experienced ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE (Anti-GBM disease) (seriousness criterion medically significant). The patient was treated with CYCLOPHOSPHAMIDE for Anti-GBM disease, at an unspecified dose and frequency. At the time of the report, ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE (Anti-GBM disease) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE (Anti-GBM disease) to be possibly related.    Concomitant product use was not provided by the reporter.   Treatment information was not provided. Patient was also treated with Steroids and plasma exchange.  This is a literature case concerning a 60-year-old, female patient with no relevant history, who experienced the unexpected serious event of  ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE (Anti-GBM). The event occurred approximately 1 to 14 days after the administration of  a dose of mRNA-1273 Moderna vaccine ( doen´t clarify if it was 1st or 2nd dose). The rechallenge was not applicable. The benefit-risk relationship of Spikevax is not affected by this report.   This case was linked to MOD-2021-371390, MOD-2021-371390 (Patient Link).; Sender's Comments: This is a literature case concerning a 60-year-old, female patient with no relevant history, who experienced the unexpected serious event of  ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE (Anti-GBM). The event occurred approximately 1 to 14 days after the administration of  a dose of mRNA-1273 Moderna vaccine ( doen´t clarify if it was 1st or 2nd dose). The rechallenge was not applicable. The benefit-risk relationship of Spikevax is not affected by this report.
Mother states 1 day after flumist she noticed sores, some coming out of nose that lasted for approximately 1 week and then went away.
Described flu-like symptoms very sore throat which feels "coated". Very sweaty, but denied any fever. Initially had swelling and 'bump like' pimples under each eye, but resolved within a day. On next day she had improvement "gargling" helped throat (had yellow phlegm). Was going to take cold and allergy medicine.
Dizziness -  Passing Out  PT moved to treatment area where he was monitored by paramedic on site -  PT moved via walking  PT +Farther
chills; chest pain\different aches going through the chest; headache; fatigue \  from the left side to the right side and is felt more when tired; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (chest pain\different aches going through the chest), HEADACHE (headache), FATIGUE (fatigue \  from the left side to the right side and is felt more when tired) and CHILLS (chills) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, the patient experienced CHEST PAIN (chest pain\different aches going through the chest), HEADACHE (headache) and FATIGUE (fatigue \  from the left side to the right side and is felt more when tired). On an unknown date, the patient experienced CHILLS (chills). At the time of the report, CHEST PAIN (chest pain\different aches going through the chest) had not resolved and HEADACHE (headache), FATIGUE (fatigue \  from the left side to the right side and is felt more when tired) and CHILLS (chills) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment  medication includes Benadryl, Ibuprofen.  The patient tried taking Benadryl which did not help and then started taking ibuprofen which has helped but the chest pain is still on going.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 04-May-2021: Reporter name and email updated. On 06-May-2021: Non Significant follow up appended. On 15-May-2021: No specific follow-up information recorded.
Noticed a 2 inch red rash on top of my left breast when I was getting undressed for the shower when I got home from work at 6:30pm. No itching, temperature 98.7.
Approx 36 hours after receiving  the vaccine I woke up feeling tired and nauseous; Approx 36 hours after receiving  the vaccine I woke up feeling tired and nauseous; Over the next 6 hours I had chills and vomited profusely  twice.; Over the next 6 hours I had chills and vomited profusely  twice.; This is a spontaneous report from a contactable consumer (Patient). A 58-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 17Dec2020 17:15 at single dose for covid-19 immunization. The COVID-19 vaccine was administered at Hospital. Medical history included sleep apnoea syndrome (OSA), High blood pressure (BP), depression, anxiety, chronic fatigue syndrome (CFS). Concomitant medication included methylphenidate hydrochloride (CONCERTA), bupropion hydrochloride (WELLBUTRIN), chlorthalidone, magnesium. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Approximate 36 hours after receiving the vaccine she woke up feeling tired and nauseous. Over the next 6 hours she had chills and vomited profusely twice. Adverse event start date provided as 19Dec2020 08:00 AM. No treatment received for the events. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient was not been tested for COVID-19. The outcome of the events was recovering.  Information on the lot/batch number has been requested.
the evening p/the inject that AM pt had 2 reddened areas on rt arm the size of a fifty cent piece about 2 inches apart; pt felt hot; pt had chills, felt weak, had tickling cough; t102 for 3 hrs; arm was sore;
chills; it is like light cold sweats; couldn't keep his legs still/His legs couldn't rest. They wouldn't stop moving.; legs hurt and ached; he curled up in fetal position in bed. He was uncomfortable; He tried to get up, and he was imbalanced; It was almost like a nervous reaction.; His body wasn't normal/His body was hurting; body was hurting; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A 70 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 04Aug2021 10:30 (Lot number: EW0164) at the age of 70 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: GABAPENTIN; LAMOTRIN. The following information was reported: NERVOUSNESS (non-serious) with onset Aug2021, outcome "unknown", described as "It was almost like a nervous reaction."; CHILLS (non-serious) with onset 04Aug2021, outcome "recovered" (2021), described as "chills"; COLD SWEAT (non-serious) with onset 04Aug2021, outcome "recovered" (2021), described as "it is like light cold sweats"; LIMB DISCOMFORT (non-serious) with onset 04Aug2021, outcome "recovered" (05Aug2021), described as "couldn't keep his legs still/His legs couldn't rest. They wouldn't stop moving."; PAIN IN EXTREMITY (non-serious) with onset 04Aug2021, outcome "recovered" (05Aug2021), described as "legs hurt and ached"; DISCOMFORT (non-serious) with onset 04Aug2021, outcome "recovered" (05Aug2021), described as "he curled up in fetal position in bed. He was uncomfortable"; FEELING ABNORMAL (non-serious) with onset Aug2021, outcome "recovered" (2021), described as "His body wasn't normal/His body was hurting"; PAIN (non-serious) with onset Aug2021, outcome "recovered" (2021), described as "body was hurting"; GAIT DISTURBANCE (non-serious) with onset 04Aug2021, outcome "recovered" (05Aug2021), described as "He tried to get up, and he was imbalanced".  No follow-up attempts are possible. No further information is expected.
Right after receiving vaccine, I had returned to my work station within our medical facility where I sat down to work on my computer when an odd feeling overcame me.  The only thing I can compare the feeling to is when I?ve had novacaine with epinephrine in it. This lead to a nervous feeling and overall it lasted about 45 minutes. I was not examined or treated. No reactions to first 2 doses so I was not expecting this. No adverse events since this initial episode.
Health Department administered Menactra, Adacel, and 2nd Varvax on 4/17/08. Client then presented to Dr. office with office for physical, and was vaccinated with additional doses of all three vaccines and a fourth dose of HPV on 8/14/08. This resulted in 4 Gardasil, 2 Menactra, 2 Adacel, and 3 Varivax vaccines administered. Parent stated that MD office administered vaccines, despite patient instructing them that she already received these vaccines in April at the Health Department Clinic. Parent was verbally upset and wanted to report this to the health department. Health Department is therefore reporting this error on behalf of the parents request. Vaccines were entered into the Immunization Registry following the 4/17/08 clinic, and were present at the time of re-vaccination at the MD office. Parent did not report any adverse reactions at the time of the call which was 24 hrs after the duplicate adminstration.
due covid situation /received / first dose on Sep 4th 2020/ never gets her second dose.; This case was reported by a pharmacist via call center representative and described the occurrence of social problem in a 79-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 4th September 2020).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced social problem. On an unknown date, the outcome of the social problem was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The pharmacist was looking for information about a Shingrix late second dose due to covid situation. The patient did not receive 2nd dose due to covid situation. The reporter consented to follow up.
Patient states that 5 hrs after vaccine administration, knees shaking together. This was followed by uncontrollable shaking of the hands, elbows, and legs. This lasted for about 2 and 1/2 hours.
Has been vaccinated against COVID-19, but on 9/5/21 he tested positive  for COVID 19 at the nursing home and since then he has shortness of breath  and cough has gotten worse and he was apparently saturating only 88% on room  air and therefore, was sent to the emergency room at DMH where workup showed  him to have a bilateral COVID pneumonia on the CT of the chest without any PE.   The patient was started on Decadron, Rocephin, Zithromax and then the  hospitalist service was called for admission.  Please note, the patient has no  history of CHF or COPD but is requiring currently 2 L of oxygen and is  saturating 93%.  A stat ABG has been ordered and the patient will be need to  be admitted as an inpatient to our COVID unit.  As per the nursing home papers  he is a DNR.  When I saw the patient he denies any headache, dizziness, chest  pain, or shortness of breath.  Does say that he has occasional cough but not  bringing up any sputum.  No nausea, vomiting, or diarrhea.  No history of any  epistaxis, hemoptysis, hematemesis, melena, hematochezia, hematuria.Was not a candidate for any remdesivir.  He was treated with the Decadron, but patient already on steroids at home. He has hypoxia has resolved.  He is back to normal himself.  Up and active to his capacity.  Normally at the assisted living facility he goes to the facility dining room in a wheelchair.  He uses wheelchair to go to the bathroom.  Here physical therapy is working with him and he seems to be doing stable from the discharge standpoint here.   Today patient is afebrile.  Has no shortness of breath cough Lungs clear Heart regular rhythm Extremity no edema scar from bilateral knee arthroplasty Physical therapy working with patient and patient's seem to be strong overall stable. Skin turgor is good. Discharged on 9/20/21
Pt. felt dizzy. Recorded by RN. Pt. left at 10:05 A.M.
Pt got vaccine on 8/23/17. On 8/24/17, he had a fever (pt did not specify how high) and didn't feel well for 24 hours. On 8/31/17, pt again had a fever of 100.5, joints hurt, severe headache. Fever lasted 2 days. On 9/1/17, his scrotum was swollen and very painful. Still having joint pain and headaches. Pt was seen in office on 9/5/17. The fever, joint pain, and headache had resolved. Pt still had swollen testicles. The swelling had decreased and they were no longer painful.
Approximately 45 seconds after patient received first dose of Pfizer Covid19 vaccine, he lost consciousness and fell out of his chair. He was rolled over and it was apparent that he was breathing normally. After approximately 5 minutes he regained consciousness and complained of dizziness. He was taken by EMS to the local hospital for further evaluation.
Pemphigoid Bullous; Itchy skin; Red skin; Broke out in blisters, the location of the reaction was torso, towards the back, legs, and arms; bilateral; Delayed reaction; This spontaneous case was reported by a consumer and describes the occurrence of PEMPHIGOID (Pemphigoid Bullous) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 06-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In May 2021, the patient experienced PRURITUS (Itchy skin), ERYTHEMA (Red skin), BLISTER (Broke out in blisters, the location of the reaction was torso, towards the back, legs, and arms; bilateral) and SKIN REACTION (Delayed reaction). On an unknown date, the patient experienced PEMPHIGOID (Pemphigoid Bullous) (seriousness criterion medically significant). The patient was treated with PREDNISONE (oral) for Pemphigoid, at a dose of 1 dosage form; DOXYCYCLINE ongoing since an unknown date for Pemphigoid, at a dose of 100 milligram twice a day; NIACINAMIDE ongoing since an unknown date for Pemphigoid, at a dose of 1 dosage form twice a day and CORTISONE (topical) ongoing since an unknown date for Pemphigoid, at a dose of 1 dosage form. At the time of the report, PEMPHIGOID (Pemphigoid Bullous), PRURITUS (Itchy skin), ERYTHEMA (Red skin), BLISTER (Broke out in blisters, the location of the reaction was torso, towards the back, legs, and arms; bilateral) and SKIN REACTION (Delayed reaction) had not resolved.            No concomitant medication details were provided. The reporter also stated that Consumer was prescribed medications for treatment, which included oral steroid, antibiotics, topical steroid, and vitamin.  Also Consumer had discontinued oral steroids.  company comment: This case concerns a  79-year-old, male patient with no relevant medical history, who experienced the unexpected event of pemphigoid bullous. The event occurred approximately 3 months after the second dose of Moderna Covid-19 vaccine. The rechallenge was unknown since no information about the first dose was disclosed. The reporter assessed the event as related to the product. The benefit-risk relationship of Moderna Covid-19 vaccine is not affected by this report.; Sender's Comments: This case concerns a  79-year-old, male patient with no relevant medical history, who experienced the unexpected event of pemphigoid bullous. The event occurred approximately 3 months after the second dose of Moderna Covid-19 vaccine. The rechallenge was unknown since no information about the first dose was disclosed. The reporter assessed the event as related to the product. The benefit-risk relationship of Moderna Covid-19 vaccine is not affected by this report.
This spontaneous report as received from a pharmacy intern refers to a 60 year old female patient. On 13-OCT-2016 the patient was vaccinated with ZOSTAVAX (lot # M027117, expiration date 27-JUL-2017), 0.65 ml, subcutaneous injection. On 15-OCT-2016 the patient went to the pharmacy and reported to a pharmacist that she developed a large area of redness and swelling at the injection site at an unspecified time after receiving ZOSTAVAX. The patient began an unspecified treatment for the redness and swelling at the injection site. The outcome of injection site erythema and injection site  swelling is unknown. No additional information was provided. Additional information is not expected as the contact information for the patient was not provided.
Pt received second dose at 3:30 pm. She woke up at 3:30 am that night (12 hours after) with a sharp pain in her head and felt nauseous and dizzy. She went to the restroom where she fainted and was out for a few seconds. She awoken and was not injured from the fall. She had a tension headache about 10 minutes later. She took an Aleve, which helped. She has not seen her doctor since and wanted this incident to be reported. She did not go to the hospital either. She is feeling fine now.
COLD SORE ON THE LIP; FEVER WHICH WAS DESCRIBED AS FLU LIKE SYMPTOMS; MUSCLE ACHE; FEELING TIRED; ITCHING; RASH THAT APPEARED ON MIDCHEST AREA BETWEEN THE STOMACH AND THE PECTORALS; RED BLOTCHES; This spontaneous report received from a patient concerned a 69 year old male. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient had no known drug allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022, and batch number: 1805022 expiry: 05-MAY-2021) dose was not reported, administered on 05-MAR-2021 for prophylactic vaccination on left arm. No concomitant medications were reported. On MAR-2021, the subject experienced itching. On MAR-2021, the subject experienced rash that appeared on midchest area between the stomach and the pectorals. On MAR-2021, the subject experienced red blotches. On 05-MAR-2021, the subject experienced fever which was described as flu like symptoms. On 05-MAR-2021, the subject experienced muscle ache. On 05-MAR-2021, the subject experienced feeling tired. On 10-MAR-2021, the subject experienced cold sore on the lip. On 17-MAR-2021, Laboratory data included: Biopsy (NR: not provided) UNKNOWN. Treatment medications (dates unspecified) included: fexofenadine, and triamcinolone acetonide. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from cold sore on the lip on 16-MAR-2021, and fever which was described as flu like symptoms, muscle ache, and feeling tired on 08-MAR-2021, and was recovering from rash that appeared on mid chest area between the stomach and the pectorals, red blotches, and itching. This report was non-serious.
Mother of the girl stated that after the second dose of the HPV vaccine the girl developed a rash through her whole body.
Patient started itching and broke-out in welts/hives all over her back. She saw her PCP to get a steroid shot, which finally helped.
SHINGLES; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 55-year-old female patient who received Herpes zoster (Shingrix) (batch number K9M5N, expiry date 7th November 2021) for prophylaxis.   On 29th August 2019, the patient received the 1st dose of Shingrix .5 ml. On 12th September 2019, 14 days after receiving Shingrix, the patient experienced shingles. The patient was treated with acyclovir. On an unknown date, the outcome of the shingles was not recovered/not resolved.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional information received were as follows: The patient received Shingrix on right arm. 2 weeks after receiving Shingrix, the patient was diagnosed with shingles. On 12th September 2019, the patient started on Acyclovir. The reporter consented to follow up.
flu; Initial information regarding an unsolicited valid non-serious social media case received from a consumer (patient) on 08-Nov-2020.  This case was linked to case 2020SA314728 (same reporter).  This case involved seven patients (with unknown demographics) who got the flu (influenza), when received INFLUENZA VACCINE.  Medical history, past medical treatment, vaccination, concurrent condition, concomitant medication and family history were not provided.   On an unknown date 45 years ago, all the patients received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer, lot number not reported) via an unknown route at an unknown administration site prophylactic vaccination.  On an unknown date (45 years ago) it was reported that, all the seven patients caught the flu (influenza) (unknown latency) following the administration of INFLUENZA VACCINE.  It was reported that vaccine was never administered again and over 45 years without a shot was doing fine.  Laboratory details were not reported.  Corrective treatment and outcome were unknown at the time of reporting.  There will be no information available on the batch number for this case.